1. Revenue growth of pharma firms to moderate to 6-7% in FY 2023: ICRA study
- Subjects
Sun Pharmaceuticals Corp. -- Forecasts and trends -- International economic relations ,Aurobindo Pharma Ltd. -- Forecasts and trends -- International economic relations ,Cipla Ltd. -- Forecasts and trends -- International economic relations ,Glenmark Pharmaceuticals Ltd. -- International economic relations -- Forecasts and trends ,Torrent Pharmaceuticals Ltd. -- Forecasts and trends -- International economic relations ,Natco Pharma Ltd. -- International economic relations -- Forecasts and trends ,Pfizer Ltd. -- International economic relations -- Forecasts and trends ,Dr. Reddy's Laboratories Ltd. -- International economic relations -- Forecasts and trends ,Wockhardt Ltd. -- Forecasts and trends -- International economic relations ,Rating agencies (Securities) -- Forecasts and trends ,Pharmaceutical industry -- International economic relations -- Forecasts and trends ,Market trend/market analysis ,Pharmaceuticals and cosmetics industries - Abstract
Byline: Our Bureau The revenue growth of its sample set of 16 Indian pharmaceutical companies is estimated to moderate to 6-7% in FY2023 after witnessing a Y-o-Y growth in revenues [...]
- Published
- 2022